Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4418285 | 0.80 | MAPK1 (0.47) | LMNAPOLBMAPK1KMT2AMEN1 | |
| SCHEMBL6026553 | 0.80 | MAPK1 (0.55) | LMNAPOLBMAPK1KMT2AMEN1 | |
| SCHEMBL1122259 | 0.78 | MAPT (0.52) | LMNAPOLBKMT2AMEN1CYP1A2 | |
| SCHEMBL784584 | 0.78 | POLB (0.48) | LMNAPOLBMAPK1KMT2AMEN1 | |
| SCHEMBL783971 | 0.76 | MAPK1 (0.53) | LMNAPOLBMAPK1KMT2AMEN1 | |
| SCHEMBL20965348 | 0.73 | MAPK1 (0.55) | LMNAMAPK1KMT2AMEN1CYP1A2 | |
| SCHEMBL3573462 | 0.70 | LMNA (0.56) | LMNAPOLBGAADGAT1 | |
| SCHEMBL18335080 | 0.70 | NPC1 (0.39) | LMNAPOLB | |
| SCHEMBL18335120 | 0.70 | MAPT (0.49) | POLBMAPK1KMT2AMEN1CYP1A2 | |
| SCHEMBL783991 | 0.69 | MAPK1 (0.50) | LMNAPOLBMAPK1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694649-B1 | 2-PYRIDINYLETHYLCARBOXAMIDE DERIVATIVES AND THEIR USE AS FUNGICIDES | BAYER SAS (FR) | 2014-01-22 | — | — | EP | disclosed |
| US-8318777-B2 | 2-pyridinylethylcarboxamide derivatives and their use as fungicides | BAYER SAS (FR) | 2012-11-27 | — | — | US | disclosed |
| US-20120071517-A1 | 2-PYRIDINYLETHYLCARBOXAMIDE DERIVATIVES AND THEIR USE AS FUNGICIDES | BAYER SAS (FR) | 2012-03-22 | — | — | US | disclosed |
| US-8071627-B2 | 2-pyridinylethylcarboxamide derivatives and their use as fungicides | BAYER SAS (FR) | 2011-12-06 | — | — | US | disclosed |
| US-20090088456-A1 | 2-Pyridinylethylcarboxamide derivatives and their use as Fugicides | BAYER CROPSCIENCE S.A. | 2009-04-02 | — | — | US | disclosed |
| US-20070117845-A1 | 2-Pyridinylethylcarboxamide derivatives and their use as fungicides | BAYER CROPSCIENCE S.A. (FR) | 2007-05-24 | — | — | US | disclosed |
| EP-1548007-A1 | 2-Pyridinylethylcarboxamide derivatives and their use as fungicides | Bayer CropScience S.A. (FR) | 2005-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088456-A1 | 2-Pyridinylethylcarboxamide derivatives and their use as Fugicides | PFAS, CYP4F2, FPGS | LMNA 1673/4885POLB 2167/4885MAPK1 4147/4885 |
| US-20070117845-A1 | 2-Pyridinylethylcarboxamide derivatives and their use as fungicides | CYP1A2, PNPO, PFAS | LMNA 2270/4885POLB 4158/4885MAPK1 3144/4885 |
| US-20120071517-A1 | 2-PYRIDINYLETHYLCARBOXAMIDE DERIVATIVES AND THEIR USE AS FUNGICIDES | CYP1A2, CYP51A1, CYP3A5 | LMNA 2942/4885POLB 4528/4885MAPK1 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.